Company Overview and News

2
PrairieSky Royalty Appoints New Independent Director

2018-06-18 globenewswire
CALGARY, Alberta, June 18, 2018 (GLOBE NEWSWIRE) -- James Estey, Chair of the Board of Directors of PrairieSky Royalty Ltd. (“PrairieSky”) (TSX:PSK) is pleased to announce the appointment of Myron M. Stadnyk, P. Eng., to the company's Board of Directors. Mr. Stadnyk’s appointment is effective June 18, 2018.
AETUF PSK PREKF ARX

1
Intelligent Artificial Lift Systems Improve Digital Oilfield Operations

2018-06-14 worldoil
World Oil TechTalk allows marketers to connect directly with the World Oil audience by enabling them to create content and participate in the conversation on the World Oil website. Each TechTalk article is produced by the marketer. For more information on TechTalk packages, click here.
AETUF ROK ARX

1
ARC Resources Optimizes Artificial-Lift Systems With Connected Production Solution From Rockwell Automation

2018-06-08 worldoil
World Oil TechTalk allows marketers to connect directly with the World Oil audience by enabling them to create content and participate in the conversation on the World Oil website. Each TechTalk article is produced by the marketer. For more information on TechTalk packages, click here.
AETUF ROK ARX

0
Arc Resources: Producing 131,000 Boe/Day But Unknown Outside Of Canada

2018-05-30 seekingalpha
Arc is a major oil and gas producer, but the low gas price is hitting its profitability results.
AETUF ARX

15
Cenovus reports voting results of election of Directors

2018-04-26 globenewswire
CALGARY, Alberta, April 25, 2018 (GLOBE NEWSWIRE) -- Cenovus Energy Inc. (TSX:CVE) (NYSE:CVE) announced that at its annual meeting of shareholders held on April 25, 2018, each of the 12 nominees proposed as Directors and listed in its Management Information Circular dated March 2, 2018 were elected as Directors. The detailed results of the vote are set out below.
AETUF NVA CVE TRP FINGF NUVSF CNQ CVE ARX BNPUF

1
Pumping Out the Dividends in the Energy Sector

2018-04-25 investorplace
U.S. crude oil has been on a great recovery over the past year with West Texas Intermediate (WTI) rising from a low of $42.53 back on June 21 to a recent high of $68.64 on Monday, April 23.
AETUF VET SLB PTORF SPE ARX

30
CANADA STOCKS-TSX edges lower as materials weigh

2018-04-25 reuters
April 25 (Reuters) - Canada’s main stock index edged lower on Wednesday, as worries over rising U.S. yields weighed on materials stocks.
AETUF CVE ACBFF TXCX KATFF ARX TECK ACB KAT CVE FQVLF TCKRF FQM

10
"Extinction" predicted for Canada energy industry without M&A

2018-04-06 worldoil
TORONTO (Bloomberg) -- Investors have bailed on the Canadian energy sector, although mergers & acquisitions (M&A) north of the border could provide a much needed catalyst, barring pipeline and political developments. Raymond James recently called upon John Connor to help save the space, and BMO Capital Markets is now calling for consolidation.
TOU AETUF CNQ WCP TRMLF SPGYF ARX

10
Canada’s Energy Industry Faces ‘Extinction’ Without M&A, BMO Says - Bloomberg

2018-04-05 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
TOU AETUF CNQ WCP TRMLF SPGYF ARX

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

20h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

21h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to TSX:ARX / Arc Resources Ltd. on message board site Silicon Investor.

Prudent Bear Fund (BEARX): contrarian investing EAR: HEARx LTD.
MXRT Marx Toys and Entertainment Marx Toys- MRXT
ARXX ARXA International (ARXA): Rapid Expansion imminent!!!!!!
ARXX: Aeroflex, Incorporated Aeroflex (ARX)
Hearx(EAR) DMRX (DermaRx Corporation) Discussion